Quick Answer
Nurix Therapeutics, Inc. reported Net Income Loss of -$264.46 million for the year ending 2025.
- Nurix Therapeutics, Inc. showed a decrease of -36.6% in Net Income Loss from 2024 to 2025.
- This data is from Nurix Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on January 28, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2019 to 2025), Nurix Therapeutics, Inc.'s Net Income Loss has declined by 1,118.8%.
- Historical annual values: Fiscal year 2025: -$264.46 million | Fiscal year 2024: -$193.57 million | Fiscal year 2023: -$143.95 million | Fiscal year 2022: -$180.36 million | Fiscal year 2021: -$117.19 million | Fiscal year 2020: -$43.24 million | Fiscal year 2019: -$21.70 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: